Latest Amgen Inc. Stories
MarketResearchReports.Biz announces addition of new report “Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive
2013 GAAP EPS Were $6.64 THOUSAND OAKS, Calif., Jan. 28, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2013.
MarketReportsOnline.com offers “Global Rheumatoid Arthritis Market: Trends and Opportunities (2013-2018)” in its store.
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.